XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
  Memory
  Regeneration
  Stroke
  Brain Diseases
  Headache
  Spinal Cord Diseases
  Demyelinating Diseases
   Multiple Sclerosis
  Neurodegenerative Diseases
  Taste
  Trigeminal Neuralgia
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Multiple Sclerosis Channel
subscribe to Multiple Sclerosis newsletter

Latest Research : Neurosciences : Demyelinating Diseases : Multiple Sclerosis

   DISCUSS   |   EMAIL   |   PRINT
Naltrexone for HIV/AIDS, Cancer, and Autoimmune Diseases such as Multiple Sclerosis?
Apr 19, 2005, 11:10, Reviewed by: Dr.

This discovery establishes a new paradigm in medical therapy: LDN not only tends to normalize the immune system by elevating the body�s endorphin levels but also accomplishes its results with virtually no side effects or toxicity.

 
The drug naltrexone, which in a 50 mg dose was approved by the FDA many years ago for drug abuse and for alcoholism, in less than one-tenth that dosage boosts the immune system and thus helps fight any disease that is characterized by inadequate immune function.

Investigators mounting successful clinical trials, along with physicians and patients utilizing low dose naltrexone (LDN), will make panel presentations on June 11th at a conference to be held at the New York Academy of Sciences. The keynote speaker will be Bernard Bihari, MD, a Manhattan physician and the discoverer of the clinical effects of LDN.

This discovery establishes a new paradigm in medical therapy: LDN not only tends to normalize the immune system by elevating the body�s endorphin levels but also accomplishes its results with virtually no side effects or toxicity.

Two pilot studies have recently been completed, one for Crohn�s disease and one for multiple sclerosis (MS), and the principal investigators, respectively from Hershey Medical Center at Penn State and from Dr. Evers Clinic, a hospital for neurological disease in Germany, will be present.

The promise of LDN is significant because:

(a) it can halt diseases (e.g., MS and other autoimmune diseases, HIV, and many cancers) where there are no effective treatment options;

(b) it provides successful treatment while being virtually free of side effects or toxicity; and

(c) were it produced in a developing country, this generic drug would offer an extremely inexpensive ($10 per year) HIV treatment, one that does not require close supervision by health professionals�the patient need only take one small capsule each night at bedtime.
 

-
 

Comprehensive Details Regarding LDN

 
Subscribe to Multiple Sclerosis Newsletter
E-mail Address:

 

The conference will be held on June 11, 2005 from 9am to 4pm at the New York Academy of Sciences, located at 2 East 63rd Street, between Fifth and Madison Avenues in Manhattan.

For additional information, comprehensive details regarding LDN are provided at www.ldninfo.org. The website www.remedyfind.com includes independent ratings of LDN by people with MS, who rank it far higher than any other MS medical treatment; and http://ldners.org/surveys.htm displays results of surveys of hundreds of people with MS, who are reporting striking reductions in disease progression as well as marked functional improvement on LDN alone.

Contact Information:
David Gluck, MD
212-734-5109
http://www.ldninfo.org


Related Multiple Sclerosis News

Cause of nerve fiber damage in multiple sclerosis identified
Fampridine may hold promise for treating Multiple Sclerosis
CNS can send out signals to invite autoimmune attacks
Natalizumab Re-approved for Relapsing Multiple Sclerosis
Efficacy in relapse rate reduction beyond five years shown for interferon beta 1b in Multiple Sclerosis
Systematic Review Questions Accuracy of MRI in Multiple Sclerosis
Statins could prove useful in treating MS
12.5 kda cystatin may generate first simple test for multiple sclerosis
Fatal flaw in natalizumab, multiple sclerosis drug, trial
Azathioprine reduces new brain inflammatory lesions in MS


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us